Drug Profile

APB A2

Alternative Names: Anti-CD73 IgG4; APB-A2

Latest Information Update: 03 Apr 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator APRILBIO
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

31 Mar 2023 Discontinued for Solid tumours in South Korea (Parenteral) before March 2023 (APRILBIO pipeline, March 2023)
25 Oct 2021 Early research in Solid tumours in South Korea (Parenteral), before October 2021 (APRILBIO pipeline, October 2021)
25 Oct 2021 APRILBIO plans a phase I trial for Solid tumours in South Korea, in 2023-2024 (APRILBIO pipeline, October 2021)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com